Drug Search Results
More Filters [+]

Guselkumab

Alternative Names: guselkumab, cnto 1959, cnto-1959, tremfya, cnto1959
Latest Update: 2025-01-07
Latest Update Note: Clinical Trial Update

Product Description

Guselkumab is a human monoclonal immunoglobulin G1 lambda (IgG1lambda) antibody that selectively binds to the p19 subunit of IL-23 (a protein involved in the inflammatory response) and inhibits its interaction with the IL-23 receptor. Guselkumab is used for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy (ultraviolet radiation treatment). (Sourced from: https://dermnetnz.org/topics/guselkumab)

Mechanisms of Action: IL23 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous,Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Vietnam

Approved Indications: Psoriasis

Known Adverse Events: Headache | Enteritis | Gastroenteritis | Anaphylaxis | Drug Hypersensitivity | Tuberculosis | Tinea | Arthralgia | Diarrhea | Signs and Symptoms, Respiratory | Herpes Simplex

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Guselkumab

Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Bosnia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Jordan, Korea, Latvia, Lebanon, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, North Macedonia, Norway, Philippines, Poland, Portugal, Puerto Rico, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Tunisia, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 73

Highest Development Phases

Phase 3: Arthritis, Juvenile|Arthritis, Psoriatic|Colitis, Ulcerative|Crohn Disease|Palmoplantar Psoriasis|Palmoplantar Pustulosis|Psoriasis|Pustular Psoriasis

Phase 2: Giant Cell Arteritis|Lichen Planus, Oral|Lupus Nephritis|Oral Ulcer|Pemphigus, Benign Familial|Pyoderma Gangrenosum|Scleroderma, Diffuse|Scleroderma, General|Scleroderma, Systemic|Skin Ulcer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

jRCT2031220308

P2

Recruiting

Colitis, Ulcerative

2033-10-12

TRILOGY

P3

Recruiting

Arthritis, Juvenile|Arthritis, Psoriatic|Crohn Disease|Colitis, Ulcerative

2031-12-12

CNTO1959ISD3001

P3

Unknown Status

Crohn Disease|Arthritis, Juvenile|Colitis, Ulcerative|Arthritis, Psoriatic

2031-12-12

jRCT2031220309

P2

Recruiting

Crohn Disease

2030-07-18

Recent News Events